Objective: To analyze interactions between the thyroid-stimulating hormone receptor (TSHR) and a thyroid-stimulating human monoclonal autoantibody (M22) at the molecular level.
Main outcome: TSHR260 comprises of a curved helical tube and M22 Fab clasps its concave surface at 90° to the tube length axis. The interface buried in the complex is large (2.500 Å 2 ) and an extensive network of ionic, polar, and hydrophobic bonding is involved in the interaction. There is virtually no movement in the atoms of M22 residues on the binding interface compared to unbound M22 consistent with "lock and key" binding. Mutations of residues showing strong interactions in the structure influenced M22 activity, indicating that the binding detail observed in the complex reflects interaction of M22 with intact, functionally active TSHR. The receptor-binding arrangement of the autoantibody are very similar to those reported for FSH binding to the FSH receptor (amino acids 1-268) and consequently to those of TSH itself.
Conclusions:
It is remarkable that the TSAb shows almost identical receptor-binding features to TSH although the structures and origins of these two ligands are very different. Furthermore, the structure of the TSHR and its complex with M22 provide foundations for developing new strategies to understand and control both glycoprotein hormone receptor activation and the autoimmune response to the TSHR.
COMMENT
When trying to follow the medical literature week after week, magical events happen from time to time: this is one of these magical moments, at least in the field of thyroid research. For the first time, a group of investigators in the UK have been able (after years of long and painstaking efforts) to grow crystals of the TSH receptor suitable for X-ray diffraction analysis. They now report on the molecular level binding characteristics between a part of the extracellular domain (ECD) of the TSH receptor and a potent monoclonal thyroid-stimulating auto-antibody (M22). This provides new insight on how a pathogenic antibody interacts with its target, namely the TSH receptor. The molecular details of the binding interactions will only be understood by experts in this field but, for the non experts, important messages can be taken home. For instance, the notion that the binding characteristics of the autoantibody to the receptor may help design -in the near future -small molecules that might interfere specifically with binding and, in turn, be useful for treating patients. This could open new avenues for the treatment of Graves' disease where, instead of interfering with thyroid hormone synthesis (what ATD do), new compounds could be acting at the start of the pathogenic pathways, involving thyroidal stimulation. Such compounds would also inhibit antibody binding in all tissues where the TSH receptor is functionally expressed and these autoantibodies believed to play a detrimental role, hence opening potential new approaches for the treatment of Graves' ophthalmopathy. A final interest of present work was that further analysis and comparison between the binding characteristics of both the TSH and FSH receptors will permit a greater understanding of the molecular bases of glycoprotein hormone specificity. The data were presented in the first "highlight" session at the last ETA annual meeting in Leipzig. The monoclonal stimulating antibody M22 bound to the TSH receptor in a fashion almost identical to TSH itself. Binding of M22 occurs in a large area of the leucine-rich part of the ECD in the TSH receptor. This area covers 2.500 A 2 and is buried in the interface. The binding implies complementary electrostatic binding properties, with a negatively charged zone in M22 binding to a positively charged area of the receptor (and vice versa). In the discussion of this paper in Leipzig, it was mentioned that the region studied herein (TSH-Rec 1-260) is only a part of the much larger ECD of the TSH receptor. Also, TSH itself did not bind directly to the same area (which is obviously annoying), and the only explanation provided by the authors was that M22 has apparently a stronger binding affinity to that section of the ECD of the TSH receptor than TSH itself. Thus, it is clearly not the end of the story but these new results remain nevertheless beautiful and fascinating. 
